Skip to main content

Philips introduces next-generation Digital Pathology Suite – IntelliSite – to enhance diagnostic confidence and streamline pathology lab workflows

Philips Digital Pathology Suite

Philips Pathology Scanner

October 15, 2021

  • Solution offers high quality imaging with multi-site, multi-disciplinary interoperability, artificial intelligence and Laboratory Information System integration, enhancing diagnostic confidence
  • Scalable image management system caters to the needs of all levels of pathology imaging

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of its next-generation digital pathology solution, moving digital pathology into the heart of enterprise-wide healthcare informatics. Philips Digital Pathology Suite – IntelliSite – features a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, enhance diagnostic confidence, facilitate team collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs.

Philips Digital Pathology Suite offers a range of solutions designed for different use cases with an affordable cost of ownership. From low-volume ‘spoke’ labs or small independent labs, where small batches of slides are continually processed and scanned, to medium and large labs operating high-volume batch processing workflows. The hardware is also pre-equipped for multi-layer slide scanning. Images are captured in a centralized informatics platform that has been optimized around pathologists’ workflows, integrating with leading third-party AI tools and algorithms with the aim to further reduce laboratory costs and enhance diagnostic capabilities.

“Integrated diagnostic capabilities are a cornerstone to a precise diagnosis and personalized care pathway selection for oncology patients and only when data and specialties work together in harmony can the ultimate promise of care be realized,” said Louis Culot, General Manager Oncology Informatics at Philips. “That’s why bringing together multiple pieces of the healthcare continuum – like radiology, pathology, and genomics – is the key to a new paradigm of diagnostic precision. By providing pathologists the interoperability and connectivity to share high-quality images and diagnostic insights across networks, Philips Digital Pathology Suite positions them as key stakeholders in the data-driven healthcare systems of the future.”

Digital Pathology Suite includes a range of three pathology slide scanners, as well as Pathology Workspace – Image Management System – a comprehensive set of software tools and capabilities that encompass every stage of the digital pathology process, including an advanced image management system, bidirectional interoperability into laboratory information systems, and a case viewer that facilitates multidisciplinary case reviews and care pathway selection. Diagnostic confidence is enhanced by superb image quality and advanced algorithms, such as automatic tissue shape detection and non-rectangular optimization of regions of interest. Vendor-agnostic data interoperability also allows the easy sharing of patient-centric histology data across enterprises and between sites.

“MEDIPATH is focused on accelerating the path of augmented pathology by slide digitalization on all our technical platforms. We are very excited to leverage the new Philips Digital Pathology Suite, including the Pathology Scanner SG300 and Pathology Workspace with de-identification tools, for each of our sites,” said Stephane Rossat, Director for innovation, science and project management at MEDIPATH, a French Pathology group with a network of 11 technical labs. “Following the first days of installation, the solution is already proving easy to use, with images generated more quickly, while the quality and sharpness of the images produced is experienced to be superior. The Philips Digital Pathology Suite is the solution that our organization needs to expand our digital pathology capabilities and activate our transformation [1].”

Integrated intelligence and automation across smart diagnostic systems
Precision medicine has increased the volume and complexity of workloads, with pathology labs worldwide facing a shortage of skilled staff. Within the diagnosis and staging of cancer, pathology information is combined with data from multiple disciplines, including radiology, pathology and genomics, to deliver the diagnostic precision required for highly personalized care. There is an urgent need for solutions that combine operational efficiency, team-working, expertise sharing, and enterprise-wide informatics to make the most of a pathology lab’s human resources.

Through breakthrough innovations and partnerships, Philips integrates intelligence and automation into its Precision Diagnosis portfolio, including smart diagnostic systems, integrated workflow solutions with the aim to transform departmental operations, advanced informatics that enhance diagnostic confidence, and care pathway solutions that allow medical professionals to tailor treatment to individual patients. By developing and integrating AI-enabled applications, the company aims to enhance the ability to turn data into actionable insights and drive the right care in the right sequence at the right time.

Philips Digital Pathology Suite is being showcased at the Pathology Visions 2021 event (October 17-19, Las Vegas, USA). Follow @PhilipsLiveFrom for updates on Philips participation at the event, and visit Philips Digital Pathology for more information.   

[1] Results of customer testimonies are not predictive of results in other cases. Results in other cases may vary.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.